53 results about "Cell Fraction" patented technology

A device for autologous blood transfusion includes a centrifuge unit with an autotransfusion set rotatably mounted thereto. The autotransfusion set includes a separation unit for concentrating a cell fraction by centrifugation and a tubing system for providing a connection to a blood supply. The tubing system includes a blood supply line leading to the separation unit for supplying blood to be processed and a return line leading away from the separation unit. A filter is integrated into the autotransfusion set in order to eliminate leukocytes and/or tumor cells, thereby yielding greater safety in autotransfusion.

A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject. This method has advantages to present diagnostic procedures for identifying malignant pleural effusions. The tumor cells present in pleural fluid can be characterized with cellular and molecular markers to determine prognostic and predictive factors.

Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3. The diseases for which the therapeutic use is to be examined include blood diseases in which the expression of TIM-3 is observed in bone marrow or peripheral blood, particularly blood tumor.

A method and system for conducting genomic sequencing, the system comprising a first microservice for receiving an order from a physician, the order to initiate an NGS of a patient's germline specimen and somatic specimen using a targeted-panel, a second microservice for executing an NGS of the patient's germline specimen to identify sequences of nucleotides in the germline specimen using the targeted-panel to generate germline sequencing results, a third microservice for executing an NGS of the patient's somatic specimen to identify sequences of nucleotides in the somatic specimen using the targeted-panel to generate somatic sequencing results, a fourth microservice for executing quality control (QC) testing on the germline sequencing results to generate a germline QC score and on the somatic sequencing results to generate a somatic QC score, a fifth microservice for generating at least one clinical report, and a sixth microservice for providing the at least one clinical report to the physician, the at least on clinical report comprising the patient's TMB status.

A parallel processing, fluid handling apparatus for concurrent temperature controlled preparation of a plurality of cell fraction samples adapted to be used for electron microscopic viewing. The apparatus comprises generally a sample receiving member, a fluid handling means, and a separation means. The sample receiving member comprises a plurality of discrete apertures each adapted to receive a biological sample therein. The fluid handling means for inserting and removing fluid to and from the plurality of apertures substantially in parallel, permits the biological samples to be processed substantially in parallel by the insertion and removal of processing fluid. The separation means permits the parallel isolated separation of the post-processing samples. The post-processing samples are adapted to be polymerized in embedding solution and removed from the sample receiving member.

A method of preparing nucleated peripheral blood or bone marrow cells optimized for at least dual mode imaging. The method including: (a) isolating nucleated cells from a peripheral blood or a bone marrow sample; and (b) resuspending the nucleated cells in the presence of a morphology preserver including at least 1% serum, and recovering a cell fraction thereby preparing the nucleated peripheral blood or bone marrow cells optimized for at least dual mode imaging.

This invention provides a method for concentrating and collecting small quantities of fetal nucleated red blood cells contained in the maternal blood. The method for concentrating and collecting nucleated red blood cells from the maternal blood comprises: (i) subjecting the maternal blood to a first density-gradient centrifugation and collecting a cell fraction containing nucleated red blood cells; (ii) treating the cell fraction containing nucleated red blood cells so as to selectively changes the density of the nucleated red blood cells from that of the white blood cells; and (iii) subjecting the treated cell fraction containing the nucleated red blood cells to a second density-gradient centrifugation so as to collect a fraction containing nucleated red blood cells.

The present invention relates to a method for the separation of cells, in particular for the preparation of samples in tumor diagnostics. In particular, the present invention relates to a method for sample preparation for the detection of tumor cells of solid tumors in the course of the diagnosis for prognosis and stratification of therapy, comprising the destruction of cells that make this diagnosis more difficult or entirely impossible. Furthermore, the present invention relates to a kit for the preparation of samples and for the detection of the presence of the altered cells. Finally, the present invention relates to the use of the method and the kit in the diagnostics of altered cells such as tumor cells, and the performance of a PCR reaction to detect the tumor cells in body fluids and tissues.

Human Valpha24<+> natural killer T cells are expanded by culturing a mononuclear cell fraction obtainable from human peripheral blood in which hemopoietic stem cells are mobilized by granulocyte colony-stimulating factor, in the presence of a cytokine, such as interleukin 2, effecting proliferation and/or activation of lymphocytes and alpha-glycosylceramide. A cell fraction comprising human Valpha24<+> natural killer T cells expanded by the method, is useful as a cancer-treating agent.

The present invention refers to an optimized and defined method for isolation and preservation of precursor cells from human umbilical cord. Besides being reproducible and 100% reliable, in terms of the number of samples processed, the method results in a high and defined number of precursor cells, being the majority obtained after a single adhesion and expansion/multiplication phase ex vivo (thus granting cell phenotype), in a shorter time frame than what was previously described in the state-of-the-art. With this method, it is possible to obtain, in 9 days, after direct freezing of a cell fraction, and after one expansion/multiplication phase ex vivo (end of P0) of the majority of the cells, about 8.6(±0.1)×10⁵ cells/gram of processed umbilical cord. In turn, the characteristics of the cells allow, for example, after 35 days, obtaining an average of 7.7×10¹⁵ cells, with precursor phenotype, from 100% of processed umbilical cord samples. The method, because it is simple, robust and 100% reliable, can be performed under good manufacturing practices (GMP) in laboratories dedicated to cell therapy in humans. Furthermore, the method has applications in the pharmaceutical, cosmetic and biotechnology areas.

The disclosure provides preparations of cells that are enriched in white blood cells, methods for separating cells into different fractions, and methods for administering the different cell fractions into a recipient subject.

In a method for obtaining dinitrogen monoxide by microbiological or enzymatic processes from nitrogen-containing substances, the microorganisms, bacteria, archaea, eukaryotes, fungi, parasites, phages, cells, cell fractions or membrane fractions, and/or enzymes, and/or a combination thereof to be used in this context are selected, or manipulated or partly or entirely reversibly and/or irreversibly inhibited by suitable actions, or the corresponding microbiological or enzymatic processes are controlled, for example, by way of suitable process conditions, so that, in part or entirely, dinitrogen monoxide (N₂O) is formed from the nitrogen-containing compounds of the nitrogen-containing substances.

A method is defined wherein a Master Library of individual compounds, mixtures of compounds, or reaction pre-mixtures in solvent are prepared for storage and subsequent utilization in a Distribution-Ready Library by delivery of the master stock constituents into a distribution formulation liquid (DFL). The individual compounds within the Master Library can include peptides, proteins, organic chemicals, pharmaceutical compounds, RNA, DNA, or cell fractions. The Distribution-Ready Library can be maintained indefinitely in storage. At the time of manufacture or time of need, the Distribution-Ready Library is microarrayed onto substrates at high density, thereby creating numerous Library Microarrays that are identical replicates of the Master Library compound(s) in DFL at fixed and known positions on the substrate. The DFL has a defined surface tension to maintain the Master Library compound in a non-spreading, non-beading adherent microdot, or spot, at a fixed position on the substrate in a manner that is stable for extended periods of time.

The present invention pertains to hepatocytes, liver progenitor cells, cholangiocytes, liver sinusoidal endothelial progenitor cells, liver sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells, and liver cellular tissue models, as well as to methods for preparing these cells. The present invention also pertains to a cell fraction comprising liver progenitor cells, liver sinusoidal endothelial progenitor cells, or hepatic stellate progenitor cells. The present invention also pertains to a pharmaceutical composition or kit comprising the above-mentioned cells, a liver cellular tissue model, or a cell fraction. The present invention also pertains to: a method for screening liver disease treatment agents; a method for evaluating the hepatotoxicity of drugs, hepatocytes for infectious disease models, and a method for preparing the same; infectious disease model tissues and a method for preparing the same; as well as a method for screening infectious liver disease treatment agents.

The present disclosure is directed to a method of preparing an osteogenic bone graft. The method includes introducing an anticoagulant compound into a volume of cellular material including a mononuclear cell population from the intramedullary canal of a long bone; collecting an effluent including the volume of cellular material containing the anticoagulant compound at a collection point; separating a concentrated cell fraction from the effluent, the concentrated cell fraction including the mononuclear cell population and the anticoagulant compound; and preparing an osteogenic bone graft from the concentrated cell fraction.

The present invention relates to a method for separating lymphocytes and/or stem cells from whole blood in an automated blood separation system, wherein the quality of the collected lymphocytes and/or stem cells fractions is increased and the cell collection procedure is further automated by use of an optical sensor comprised in a detector device to measure turbidity and colour in the claimed method and in a cell separator, which can be used to perform the claimed method. The method of the invention is particularly useful to collect lymphocytes and/or stem cells fractions from whole blood, wherein the contamination of the collected cell fractions by platelets, red blood cells and granulocytes is reduced.